Introduction

Clinical research into neurodegenerative and autoimmune neurological diseases is seeing significant momentum, with new therapies progressing through early-stage trials and increased awareness initiatives supporting rare condition communities. From ALS and Guillain-Barré Syndrome (GBS) to central nervous system (CNS)-specific drug targets, these advancements highlight the power of both scientific innovation and patient-centered outreach in improving outcomes for individuals with challenging neurological disorders.

MN-166 Expanded Access Program Enrolls First ALS Patient

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons, and currently has limited therapeutic options. The MN-166 (ibudilast) program, funded the NIH, has launched its expanded access initiative to provide investigational treatment to patients outside of clinical trials.

The therapy aims to slow disease progression targeting neuroinflammation and glial cell activation. Early studies have shown:

• A reduction in inflammatory markers.
• Tolerable safety profiles in long-term use.
• Potential benefits on motor function preservation.

The first patient has now been enrolled in this expanded access program, providing hope for those unable to participate in formal trials. MN-166 ALS trial first patient enrolled in NIH-funded EAP

Annexon Presents GBS Data and Launches Awareness Campaign

At the 2025 American Academy of Neurology (AAN) conference, Annexon Biosciences presented new data on its investigational therapy for Guillain-Barré Syndrome (GBS), an acute autoimmune condition in which the immune system attacks peripheral nerves.

The treatment showed early promise targeting the classical complement pathway, aiming to:

• Prevent complement-mediated nerve damage.
• Improve recovery timelines for patients with GBS.
• Offer a potential new mechanism of action distinct from IVIG or plasma exchange.

Alongside the trial data, Annexon launched a public education campaign to increase awareness of GBS symptoms, emphasizing early diagnosis and intervention. Annexon at AAN: GBS data & new education campaign

Cerevance Advances CVN293 for CNS Disorders

Cerevance has announced encouraging Phase 1 results for CVN293, a novel treatment targeting central nervous system inflammation. Presented at AAN 2025, the drug uses the company’s NETSseq platform to discover CNS-specific gene expression patterns in post-mortem human tissue, allowing for precision targeting of neuroinflammatory pathways.

Initial trial results revealed:

• Favorable safety and tolerability.
• Dose-dependent pharmacokinetics in healthy volunteers.
• Support for advancement into Phase 2 trials for neurological indications.

CVN293 represents a new class of CNS-directed anti-inflammatory agents that may treat diseases ranging from Alzheimer’s to Parkinson’s. Cerevance CVN293 shows positive Phase 1 results at AAN 2025

Conclusion

The latest progress in ALS, GBS, and CNS-targeted therapies is evidence of growing momentum in neurology research. From expanded access to promising Phase 1 results, the field is moving closer to delivering innovative, meaningful treatments to patients. For continued updates, visit Clinical Trial Vanguard.